234 related articles for article (PubMed ID: 23229485)
1. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.
Zeuli JD; Wilson JW; Estes LL
Antimicrob Agents Chemother; 2013 Mar; 57(3):1121-7. PubMed ID: 23229485
[TBL] [Abstract][Full Text] [Related]
2. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient.
Gandhi PJ; Menezes PA; Vu HT; Rivera AL; Ramaswamy K
Am J Health Syst Pharm; 2003 Dec; 60(23):2479-83. PubMed ID: 14686224
[TBL] [Abstract][Full Text] [Related]
3. OTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy.
Elbey MA; Cil H; Onturk E; Islamoglu Y
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):100-2. PubMed ID: 22338554
[TBL] [Abstract][Full Text] [Related]
4. Effects of three fluoroquinolones on QT analysis after standard treatment courses.
Tsikouris JP; Peeters MJ; Cox CD; Meyerrose GE; Seifert CF
Ann Noninvasive Electrocardiol; 2006 Jan; 11(1):52-6. PubMed ID: 16472283
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole-induced QT interval prolongation and torsades de pointes.
Aypar E; Kendirli T; Tutar E; Çiftçi E; Ince E; Ileri T; Atalay S
Pediatr Int; 2011 Oct; 53(5):761-763. PubMed ID: 21955009
[No Abstract] [Full Text] [Related]
6. QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors.
Berger FA; Monadian N; de Groot NMS; Santbergen B; van der Sijs H; Becker ML; Broers AEC; van Gelder T; van den Bemt PMLA
Br J Clin Pharmacol; 2018 Feb; 84(2):369-378. PubMed ID: 29057492
[TBL] [Abstract][Full Text] [Related]
7. Torsades de pointes associated with voriconazole use.
Philips JA; Marty FM; Stone RM; Koplan BA; Katz JT; Baden LR
Transpl Infect Dis; 2007 Mar; 9(1):33-6. PubMed ID: 17313469
[TBL] [Abstract][Full Text] [Related]
8. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
Makaryus AN; Byrns K; Makaryus MN; Natarajan U; Singer C; Goldner B
South Med J; 2006 Jan; 99(1):52-6. PubMed ID: 16466123
[TBL] [Abstract][Full Text] [Related]
9. Inherited long QT syndrome revealed by antifungals drug-drug interaction.
Eiden C; Peyrière H; Tichit R; Cociglio M; Amedro P; Blayac JP; Margueritte G; Hillaire-Buys D
J Clin Pharm Ther; 2007 Jun; 32(3):321-4. PubMed ID: 17489884
[TBL] [Abstract][Full Text] [Related]
10. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
[TBL] [Abstract][Full Text] [Related]
11. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
Muzyk AJ; Rayfield A; Revollo JY; Heinz H; Gagliardi JP
Drug Saf; 2012 Jul; 35(7):547-53. PubMed ID: 22702639
[TBL] [Abstract][Full Text] [Related]
12. QTc prolongation during levofloxacin and triazole combination chemoprophylaxis: Prevalence and predisposing risk factors in a cohort of hematopoietic cell transplantation recipients.
Moghnieh R; Khalil A; Bizri N; Francis N; Imad S; Mezher M; Mrad Z; Ibrahim J; Zahran K; Farroukh F; Itani M; Assaad A; Sinno L; Abdallah D; Ibrahim A
J Oncol Pharm Pract; 2023 Apr; 29(3):534-542. PubMed ID: 35075933
[TBL] [Abstract][Full Text] [Related]
13. Concomitant use of levofloxacin and fluconazole leading to possible torsades de pointes.
Tilton JJ; Sadr R; Groo VL
J Oncol Pharm Pract; 2019 Dec; 25(8):2004-2006. PubMed ID: 30501378
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors.
Gueta I; Loebstein R; Markovits N; Kamari Y; Halkin H; Livni G; Yarden-Bilavsky H
Eur J Clin Pharmacol; 2017 Sep; 73(9):1181-1185. PubMed ID: 28624887
[TBL] [Abstract][Full Text] [Related]
15. QTc Prolongation Associated With Psychiatric Medications: A Retrospective Cross-Sectional Study of Adult Inpatients.
Shao W; Ayub S; Drutel R; Heise WC; Gerkin R
J Clin Psychopharmacol; 2019; 39(1):72-77. PubMed ID: 30531476
[TBL] [Abstract][Full Text] [Related]
16. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
17. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients.
Tisdale JE; Jaynes HA; Kingery JR; Mourad NA; Trujillo TN; Overholser BR; Kovacs RJ
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):479-87. PubMed ID: 23716032
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients.
Tisdale JE; Jaynes HA; Kingery JR; Overholser BR; Mourad NA; Trujillo TN; Kovacs RJ
Circ Cardiovasc Qual Outcomes; 2014 May; 7(3):381-90. PubMed ID: 24803473
[TBL] [Abstract][Full Text] [Related]
20. Long QTc interval and torsade de pointes caused by fluconazole.
Pham CP; de Feiter PW; van der Kuy PH; van Mook WN
Ann Pharmacother; 2006; 40(7-8):1456-61. PubMed ID: 16849620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
